List of Artificial Intelligence Companies in Texas - 33

Accel Diagnostics is medical diagnostic company developing proprietary point-of-care diagnostic assay for the diagnosis, monitoring and management of a wide variety of medical conditions. We are dedicated to making a difference in the quality of life of millions of patients through technology and innovation. AccelDx’s technology enables patients and healthcare providers to perform lab-quality medical diagnostic tests anytime and anywhere. The Company's patented platform technology transforms the patient blood testing paradigm, from lab-centered to near-patient. The technology bringing significant advantages in terms of simplicity, time to result, care delivery, and cost over current standard lab-based diagnostics. During COVID-19 pademic Accel Diagnostics began to operate the ADX Diagnostic Lab to provide high quality COVID testing in Houston, TX.

Are you ready for a transformative leap in small bowel capsule endoscopy? Meet ProScan, our cutting-edge AI Assisted Reading Tool meticulously designed to revolutionize the diagnostic process for patients suspected of small bowel bleeding. ProScan leverages advanced artificial intelligence algorithms to significantly reduce the time required for reviewing capsule endoscopy studies, enabling quicker and more precise diagnoses. It is meticulously engineered to expedite the evaluation of capsule endoscopy images, enhancing the timeliness of a diagnosis and initiation of therapy. Headquartered in Plano, Texas, AnX Robotica brings versatility in development and integration of multi-discipline technologies such as precise magnetic, robotic control, in house ASIC design, artificial intelligence, micro-optical imaging, image processing, and wireless transmission. With more than 200 patents granted or applications pending, and dozens of clinical papers published in major international journals, AnX Robotica, together with its sister companies, have become the leading companies in robotic capsule technology.

Artificial accelerates the pace of life science discoveries by making connecting and orchestrating labs easy with its cloud-based software platform, the Artificial Product Suite. As a vendor-agnostic platform, the Artificial connects with any native instruments, devices, databases, and informatics to provide a single, easy-to-use orchestration layer for the entire lab. Using Artificial, scientific labs can control and monitor their processes in real-time while capturing AI-ready data and keeping humans in the loop.

Our vision is a world transformed by insect technology. Our mission is to harness the combined powers of technology and nature to pioneer the future of sustainable farming. We are creating tomorrow's traditions through breakthrough innovations that are in harmony with our largest stakeholder: our planet. We believe in technology that unleashes, rather than replaces, the incredible treasures of our natural world. We Aspire to a world that is abundant in planet-based nutrition that is better for people, pets and plants. Every company's culture is defined by its people and their actions. Who we are is the direct product of what we do and what we value. At Aspire, our culture is defined by the following attributes which spell the name of our company: • Audacity (we are competitive, innovative, and dream big) • Skill (we are competent, data-driven, and curious) • Passion (we are impact-centered, profit-minded, and market-driven) • Integrity (we are ethical, trusting, humble and candid) • Resilience (we face adversity and setbacks with fierce determination and collaboration) • Excellence (we aim to be world class in everything we do and believe generosity is a competitive advantage)

Castle Biosciences (Nasdaq: CSTL) is a leading diagnostics company improving health through innovative tests that guide patient care. The Company aims to transform disease management by keeping people first: patients, clinicians, employees and investors. The Company’s innovative portfolio of commercial and pipeline tests targets unmet clinical need along the patient care continuum. Castle currently markets six proprietary tests designed to answer clinical questions and address treatment plan challenges facing physicians in dermatologic cancers, Barrett’s esophagus, mental health and uveal melanoma. DecisionDx®-Melanoma, Castle’s test for invasive cutaneous melanoma, is a proprietary gene expression profile (GEP) test that uses an individual patient’s tumor biology to predict the risk of metastasis or recurrence, as well as the risk of sentinel lymph node positivity, independent of traditional staging factors. DecisionDx®-SCC is the Company’s GEP test that predicts the risk of metastasis in patients with cutaneous squamous cell carcinoma, who have one or more risk factors. MyPath® Melanoma provides a highly accurate, objective result to aid dermatopathologists and dermatologists in characterizing suspicious pigmented lesions. TissueCypher® Barrett’s Esophagus is the world’s first precision medicine test designed to predict future development of esophageal cancer in patients with Barrett’s esophagus. IDgenetix is Castle's pharmacogenomic (PGx) test for depression, anxiety and other mental health conditions designed to analyze a patient’s genetic make-up to guide timely and evidence-based decisions on the optimal drug for each patient. DecisionDx®-UM, the standard of care in uveal melanoma staging, is Castle's GEP test that predicts the risk of metastasis for patients with uveal melanoma, a rare eye cancer. Castle Biosciences is based in Friendswood, TX, (a suburb of Houston) and has laboratory operations in Phoenix, AZ, and Pittsburgh, PA.

CellChorus conducts dynamic single-cell analysis at scale. Time-lapse Imaging Microscopy in Nanowell Grids (TIMING) uses visual AI to evaluate how cells exist in motion. CellChorus is a single-cell, visual AI company that is the leader in visual AI for single-cell analysis.

Clinion is a leading global clinical trial company renowned for its award-winning solutions that drive innovation and excellence in the field of clinical research. We implement cutting edge technologies like AI/ML and GenAI to accelerate clinical trials for better outcomes. Our unparalleled expertise empower pharmaceutical, biotechnology, and medical device companies to conduct clinical trials more efficiently and effectively. Join us in revolutionizing the future of clinical trials and making a lasting impact on global healthcare. Facebook : https://www.facebook.com/clinion Twitter : https://twitter.com/clinion YouTube : https://www.youtube.com/c/Clinion Instagram : https://www.instagram.com/clinion_ai/

The science of genetics. The business of discovery. Colossal is a breakthrough bioscience and genetic engineering company that builds radical new technologies to advance the field of genomics. Colossal creates disruptive technologies for extinct species restoration, critically endangered species protection and the repopulation of critical ecosystems that support the continuation of life on Earth. The company is the first to apply CRISPR technology for the purposes of species de-extinction, beginning with the woolly mammoth. Colossal is accepting humanity's duty to restore Earth to a healthier state, while also solving for the future economies and biological necessities of the human condition through cutting-edge science and technologies.

MAVEvidence is the premier functional evidence resource for the clinical genetics community. MAVEvidence delivers increased productivity and time savings through comprehensive curation, rigorous analysis, and clear presentation of functional evidence derived from high-throughput studies of genetic variants. The MAVEvidence platform contains more than 187,000 pieces of evidence across 125,000 genetic variants, and is continually updated with data from the latest functional studies.

CompuGroup Medical is a leading provider of healthy solutions for healthy patients and healthy providers. We offer integrated electronic health records, practice management software, revenue cycle management solutions, and credentialing services for physician practices and enterprises. Founded by physicians, the company is an industry leader for usable, connected software that enables physician productivity and a superior clinical experience. eMDs software has received top rankings in physician and industry surveys including those conducted by the American Academy of Family Physicians’ Family Practice Management, AmericanEHR™ Partners, MedScape®, and Black Book®. For more information, please visit http://www.emds.com.

Enthought specializes in digital transformation of science-driven companies in the materials science, chemistry, semiconductor, life science, and energy industries. In today's competitive global business environment, it's imperative that R&D organizations move from the traditional human-centric model to a digital, compute-centric infrastructure. Enthought is expert in this transition. We have been providing technical consultation and implementation services for scientific R&D for over 20 years.

Everlum Bio is pioneering a novel approach to drug development for rare diseases. As opposed to working on a single disease we are doing "Drug Development as a Service". We are relentlessly focused on innovating the drug development process. Ultimately we believe this approach will usher in a personalized/precision medicine revolution.

FAR Biotech is a preclinical, computational drug discovery company that focuses on hard-to-drug targets that have high scientific and commercial value. Founded by Dr Martin Martinov after 25 years in academia and industry -- and named after the Bulgarian word “far” that translates into “lighthouse” or “beacon” -- FAR seeks to shine a light on drug discovery in areas of high unmet clinical need. FAR's proprietary technology can more rapidly identify novel, structurally diverse, optimized, lead molecules that other approaches would not look for, let alone find. The key differentiator is FAR's complete and rigorous quantum mechanical representation of drug-target interactions -- which embeds the advantages of quantum similarity and multi-property optimization for hit and lead identification -- augmented by AI / machine learning & big data. FAR's quantum biomodelling platform has been validated preclinically across a number of therapeutic areas, including neurodegeneration, oncology and infectious diseases.

Form empowers scientists to harness the data, computing power and collaboration that drive how today's breakthroughs are made.

iBio is an innovator biologics company developing therapeutics and vaccines for the betterment of human and animal health with pipeline candidates targeting systemic sceleroderma (IBIO-100), COVID-19 (IBIO-200 and IBIO-201), and classical swine fever (IBIO-400). iBio’s subsidiary, iBio CDMO is a global leader in plant-based manufacturing.

Ikonopedia is a next-generation breast radiology reporting and patient tracking system. Our closed-loop system is automated to track and monitor patients to full resolution of all clinical concerns. Clinical reports are clear, consistent, and 100% compliant with the ACR BI-RADS® Atlas 5th Edition. Ikonopedia is MQSA-compliant and offers screening and diagnostic modalities that will improve patient safety and save valuable time for the radiologist and staff.

Kiromic BioPharma is an allogeneic Gamma Delta T-cell therapy company featuring unique, proprietary, end-to-end bioinformatic, AI targeting, and manufacturing technologies to address solid tumors. We are a clinical-stage, fully integrated biotherapeutics company using its proprietary DIAMOND® artificial intelligence (AI) 2.0 target discovery engine to develop and commercialize cell therapies focusing on immuno-oncology. Kiromic is developing a multi-indication allogeneic cell therapy platform that exploits the natural potency of Gamma Delta T-cells to target solid tumors. Kiromic’s DIAMOND® AI is where data science meets target identification to dramatically compress the years and hundreds of millions of dollars required to develop a live drug. The Company maintains offices in Houston, Texas. To learn more, visit www.kiromic.com and connect with us on Twitter and LinkedIn.

Lantern Pharma Inc., a clinical stage oncology biotechnology company, focuses on the development of precision oncology therapeutics using artificial intelligence, genomics, and machine learning. Its advanced drug candidate is LP-100, which is in phase II clinical trials to treat metastatic, castration-resistant, prostate cancer. The company also develops LP-300 as a combination therapy for female non or never-smokers with non-small cell lung cancer adenocarcinoma. In addition, its preclinical development drug candidate is LP-184, an alkylating agent that damages DNA in cancer cells that overexpress certain biomarkers and is from the fulvene class of compounds. The company was incorporated in 2013 and is based in Dallas, Texas.

MedCognetics provides an advanced AI software platform which integrates into the radiology workflow. The AI platform is trained on a diverse global patient dataset to mitigate data biasing. The future of AI in healthcare is unbiased services and MedCognetics is at the forefront of creating more predictable medical outcomes and ultimately saving lives. Founded in 2020, the company is based in Dallas, Texas. For more information, please visit our website at www.medcognetics.com.

Octagos Health is a dynamic and rapidly growing healthcare technology company dedicated to improving patient outcomes through AI-driven solutions. Octagos provides a cloud-based platform that aggregates remote and in-person device interrogations for all cardiac rhythm management (CRM) manufacturers, wearables (Holter, MCT, etc.) and remote physiologic monitoring (RPM).

Owl Therapeutics, a spin-out of Gryphon Bio, is a clinical-stage biopharmaceutical company created to develop best-in-class, artificial intelligence (AI)- and diagnostic-powered therapeutics for traumatic brain injury (TBI) and brain health. The company has rapidly built a promising, diversified pipeline of small and large molecule medicines poised to address the highly unmet needs of patients with neurodegenerative disease. Owl is led by a proven, cohesive, interdisciplinary, and internationally recognized team with deep scientific, clinical, and business experience in drug development and commercialization.

CONNECTING THE HUMAN BRAIN What if we could restore or enhance function using the power of AI and advanced technology? Our direct data interface enables this connection. MISSION We are building a high data-rate brain computer interface (BCI) to provide technology solutions for people with neurological and brain-related conditions. Our first clinical application will help severely motor-impaired people communicate, enabling social connection and restoring independence. ABOUT Paradromics was founded in 2015 by a team of engineers and neuroscientists, received early support from both NIH and DARPA, and is currently backed by venture capital.

Tackling a global health threat like antimicrobial resistance is not for the faint of heart, but the experienced and innovative team at Pattern Bioscience is on a mission to do it. Each year, drug-resistant bacterial infections claim more than a million lives globally and cost our healthcare system billions of dollars. Traditional diagnostic methods for bacterial infections remain rooted in slow, cumbersome, decades-old technology that contributes to sub-optimal treatment and the misuse of broad-spectrum antibiotics. The Pattern system is different. We’re developing the world’s only culture-free, rapid diagnostic technology that will reduce the time needed for pathogen identification (ID) and antibiotic susceptibility test (AST) results from days to hours. Our technology combines single-cell analysis of microorganisms with machine learning tools to deliver fast, clinically actionable information. The result? Patients get the right treatment faster, to save lives, prevent side effects and reduce healthcare costs.

Perimeter Medical Imaging AI is a pioneering medical technology company driven to transform cancer surgery with advanced imaging tools. We can't imagine how frustrating it is for surgeons to do everything they can and still have to make the "dreaded call" to the patient. That's why we developed our OCT technology that provides 10x the resolution of X-ray and ultrasound at 2mm imaging depth for real-time insight, so surgeons can act in the moment with greater certainty. A Toronto-based company established in 2013, with U.S. headquarters in Dallas, Texas, Perimeter seeks to harness the power of big data, artificial intelligence, and machine learning technology to further our mission of improving the standard of care, providing better long-term outcomes for patients, and reducing healthcare costs.

Phantom Neuro is creating the first minimally invasive peripheral neural interface, the Phantom X. Our technology allows complex electronic systems, like prosthetic limbs, to operate like natural extensions of the human body. We are a group of forward thinking individuals on a mission to help people with function-limiting injuries.

PhotoSound Technologies, Inc. was founded in September 2015 in Houston, Texas USA to develop and commercialize new biomedical imaging technologies based on optics and photoacoustics. Photoacoustic tomography (PAT) is a biomedical imaging modality combining the molecular sensitivity of optical probes with the spatial resolution of ultrasound that is ideal for a multitude of applications that can be used for pre-clinical research.

Praedicare Inc. is a System of Systems based end-to-end drug development company [from drug discovery to phase IV trials] that uses preclinical wet lab models mathematically mapped to patients for quantitative prediction of clinical trial outcomes, significantly reducing clients' risk, time, and costs of developing safe and effective new drugs. Praedicare is headquartered in Dallas, Texas, but has international offices and has clients from around the globe.

Our mission is to optimize the release cycle, reduce cost, and eliminate compliance risk of releasing promotional materials in the pharmaceutical industry, while improving quality and consistency. ‍ We achieve this by applying deep industry knowledge in cutting-edge technology to automate the compliance requirements and best practices for our customers. We strive not only to uphold the highest standards of accuracy and compliance, but also to enable the generation of data-driven, personalized, and engaging content that results in positive patient outcomes. At the heart of our offerings is our AI-driven platform that learns from regulations, industry best practices, and our customers’ historical actions. Recommendations provided by our platform significantly reduce promotional material release time, and this level of efficiency has already earned us the trust of a Top 5 pharmaceutical company. At Revisto, we believe in transparency and understand that trust is earned through consistent performance and open communication. We are committed to delivering results for our customers and fostering relationships built on mutual respect and shared success.

Seno Medical is leading commercialization efforts in opto-acoustic imaging of breast cancer. Seno's opto-acoustic technology combines both laser optics and conventional ultrasound technology to provide fused functional and anatomical imaging in real time. The result is an imaging device that delivers additional functional information regarding breast masses and increases confidence in making a breast biopsy decision. For more information or to answer any questions call 210-615-6501 or email digitalmarketing@senomedical.com. Seno's Imagio® Breast Imaging System (9005) received the CE Mark (April 2014) and has completed a post-market surveillance and clinical follow-up study in Europe. The newest version (9100) is approved by the FDA for commercial distribution in the U.S.

At Solugen, we believe planet-scale change starts with the chemistry we use every day. We’re revolutionizing how things are made with the world’s first carbon negative molecule factory: the Bioforge. Harnessing the power of evolved enzymes, plant-based feedstocks, and clean, catalytic reactions, we are making the materials we need to sustain life on Earth—faster, cheaper, and without emissions or waste.

Spectral AI, Inc. is a Dallas-based predictive AI company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, with initial applications involving patients with burns and diabetic foot ulcers. The Company is working to revolutionize the management of wound care by "Seeing the Unknown®" with its DeepView® System. DeepView® is a predictive diagnostic device that offers clinicians an objective and immediate assessment of a wound's healing potential prior to treatment or other medical intervention. With algorithm-driven results and a goal of changing the current standard of care in the future, DeepView® is expected to provide faster and accurate treatment insight towards value care by improving patient outcomes and reducing healthcare costs.

Helping Improve Patient Outcomes Surgilogix is a leading provider of human tissue allografts that support surgeons and physicians in their efforts to improve the quality of life for their patients. Our amniotic tissue allografts are used to cover, protect and heal wounds and our allograft bone is used to fill bone voids and defects.

Windmill Cardiovascular Systems has developed a new pumping paradigm to deliver synchronous, pulsatile, low-shear flow to support patients with end-stage heart failure. The Toroidal Ventricular Assist Device (TORVAD) has the potential to reduce the high adverse event rates associated with current VADs, which could improve the survival and quality of life for patients.